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Abstract: Attention-deficit/hyperactivity disorder (ADHD) is a highly disruptive childhood-
onset disorder that often persists into adolescence and adulthood. Comorbidity with other 
problems, such as autism, dyslexia and conduct disorder (CD) is very common. Although 
little is known about the pathophysiology of ADHD, family, twin and adoption studies have 
shown that it is highly heritable. Whole genome linkage studies suggest there are no common 
susceptibility  genes  of  moderate  effect  size.  Most  published  research  has  been  based  on 
functional candidate gene studies. The most consistent evidence for association with ADHD 
relates to a dopamine D4 receptor (DRD4) gene variable number tandem repeat (VNTR), a 
dopamine D5 receptor (DRD5) gene microsatellite and a dopamine transporter (DAT1) gene 
VNTR. In addition, the catechol-O-methyltransferase (COMT) val158/108 met variant has been 
shown to increase risk for associated antisocial behavior. The first genome-wide association 
studies (GWAS) of ADHD have been completed and although larger studies are still required 
to detect common risk variants, novel risk pathways are being suggested for ADHD. Further 
research on the contribution of rare variants, larger genome-wide association and sequencing 
studies and ADHD phenotype refinement is now needed.
Keywords: attention-deficit/hyperactivity disorder (ADHD), genetics, molecular genetics, 
genome-wide association study (GWAS), gene-environment interplay
Introduction
Attention-deficit/hyperactivity disorder (ADHD) is one of the most common 
  childhood-onset psychiatric disorders affecting 1.4%–6% of school children. The 
core clinical features are severe impulsiveness, lack of concentration and motor 
hyperactivity that result in impaired functioning in more than one setting (eg, home 
and school). This pattern of symptoms puts children at risk of education failure and 
disrupts family, teacher and peer relationships. ADHD is often accompanied by other 
psychiatric   disorders and learning difficulties, notably oppositional defiant disorder 
(ODD), conduct disorder (CD), autism and dyslexia. ADHD is highly heritable and the 
investigation of genetic factors that increase risk can help elucidate its   pathophysiology. 
The first part of this review discusses evidence on the genetic contribution to ADHD 
as well as specific clinical aspects, while the second part deals with molecular   genetics 
studies.
ADHD phenotype and diagnosis
The use of internationally accepted diagnostic criteria has increased diagnostic 
  reliability resulting in ADHD being one of the best-validated clinical diagnoses.1 Neuropsychiatric Disease and Treatment 2010:6 submit your manuscript | www.dovepress.com
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There are two sets of diagnostic criteria used to define 
ADHD: the Diagnostic and Statistical Manual of Mental 
Disorders, fourth edition, text revision (DSM-IV-TR) and 
the International Classification of Diseases, tenth edition 
(ICD-10;   Hyperkinetic Disorder). The diagnosis of ADHD 
is based on reported symptoms. Most genetic studies have 
utilized standardized diagnostic criteria, although some 
have considered ADHD to be continuously distributed and 
assessed total ADHD symptom scores.
There is consistent evidence that ADHD is familial. 
Family studies of ADHD have reported increased rates of 
ADHD among parents and siblings of children with ADHD 
compared with relatives of unaffected controls. The relative 
risk in first degree relatives is considered to be between 4 
and 5.4.1 It is interesting that half siblings of children with 
ADHD have a lower risk of developing the disorder than full 
siblings, further highlighting the important role of inherited 
factors in ADHD.2
Adoption studies are able to disentangle the contribution 
of inherited and environmental factors. Five adoption studies 
have shown that the risk of ADHD is greater in biologically 
related relatives of affected individuals than in those who 
are unrelated and this provides strong evidence for a genetic 
contribution to ADHD.3,4
Twin studies examine the contribution of inherited factors 
by examining the extent of disease concordance in   genetically 
identical (monozygotic) and nonidentical (dizygotic) twin 
pairs. Many of these studies have focused on ADHD symptom 
scores, since a large-scale twin study has found that ADHD 
may be better viewed as the extreme end of a continuum 
rather than as a category.5 Such studies have all shown that 
ADHD is highly heritable and that 60%–90% of phenotypic 
variance can be explained by inherited factors.1,6 These high 
heritability estimates are comparable to those found for other 
neurodevelopmental disorders such as autism and schizo-
phrenia. It is striking that heritability estimates are not 100%, 
meaning that there must be   additional contribution from 
nonshared environmental factors, epigenetic and stochastic 
(random) effects or measurement inaccuracies. Epigenetic 
effects are heritable but reversible genetic changes that are 
not attributable to DNA sequence variation. They have been 
hypothesized to mediate the effects of environmental risks 
on psychiatric disorders.7
Twin studies have highlighted important issues about the 
measurement of ADHD as clinical information is   usually 
gathered from different informants. ADHD scores derived 
from mother’s reports have been found to be highly heritable 
with heritability estimates of 60%–91%.8 ADHD scores from 
teacher reports are also heritable. It seems that the most reli-
able and heritable phenotype is achieved when combining 
both parent and teacher reports.9 Although using both parent 
and teacher reports appears to be the best option for defining 
child ADHD, self reports need to be considered when inves-
tigating adolescent and adult ADHD. Adolescents and adults 
with ADHD have similar patterns of   psychiatric comorbid-
ity and neurocognitive deficits to children with ADHD, 
although inattention is more prominent than hyperactivity-
impulsiveness.10 According to twin studies, the heritability 
of ADHD symptoms derived by self reported ADHD scores 
in adolescents and adults is much lower than for ADHD 
symptoms derived from parent and teacher reports of child 
ADHD scores. Nonshared environmental factors, including 
measurement errors have been thought to explain the low 
heritability.
In summary, there is abundant evidence of a strong 
genetic contribution to ADHD. However, the influence of 
noninherited factors is also important. The evidence sup-
ports the use of both parent and teacher reports for defining 
ADHD in children. For adolescents and adults, where this is 
not feasible, self reports should be treated with caution when 
no other informant (such as a partner) is available.
ADHD subtypes
The DSM-IV-TR recognizes three ADHD subtypes. The 
combined type is diagnosed when six or more symptoms 
from each of two symptom categories (inattentive and 
hyperactive-impulsive) are present, while the inattentive or 
hyperactive-impulsive type is diagnosed when six or more 
symptoms from only one of the two categories are present. 
However, it is difficult to assess whether these subtypes are 
genetically distinct. The picture from family studies is not 
clear, although a meta-analysis suggested that there is overlap 
in terms of shared familial factors and only a small familial 
effect on subtype distinction.11 Twin studies have also found 
shared genetic liability12 although findings are not entirely 
consistent as other studies report distinct genetic and environ-
mental contributions to the subtypes.9 In summary, although 
ADHD subtypes are recognized for diagnostic purposes, 
the evidence for distinct risk factors operating on different 
ADHD subtypes is not consistent.
Developmental course
At least half of those with childhood ADHD will still 
meet full diagnostic criteria in adolescence.13 The levels 
of overactivity and impulsiveness tend to decrease, while 
  inattentiveness is more persistent. During adolescence Neuropsychiatric Disease and Treatment 2010:6 submit your manuscript | www.dovepress.com
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the problems of antisocial behaviour and substance abuse 
also emerge. Longitudinal studies have shown that ADHD 
  symptoms and comorbid antisocial behavior also tend to per-
sist into adulthood.14 Twin studies find that there are genetic 
influences not only on ADHD but also on its continuity. 
Most of the continuity in ADHD symptoms is attributable 
to genetic influences.15 There is also the suggestion that a 
persistent diagnosis of ADHD is associated with stronger 
family history.1 Interestingly, despite diagnostic continuity 
over time, there are also reports of distinct genetic factors 
contributing to child and adult ADHD.16 In summary, ADHD 
is a persistent disorder with genetic factors contributing to 
its origins and persistence.
Comorbidity
Comorbidity is common and around two thirds of   children 
with ADHD have a diagnosis of another psychiatric 
  disorder. It is increasingly recognized that autism and other 
pervasive developmental disorders (PDD), which are also 
  neurodevelopmental in origin, often co-exist with ADHD. 
Common characteristics of neurodevelopmental disorders 
include a tendency to more commonly affect males17,18 and 
having an onset in childhood. It has been suggested that 
there might be a set of common risk factors   affecting brain 
  development during critical stages that lead to such   disorders. 
Twin studies indeed do find that ADHD and autism   symptoms 
are influenced by a shared inherited risk.19,20 Further genetic 
or environmental factors may then be responsible for the 
manifestation of symptoms leading to diagnoses of specific 
disorders. It is striking that children with PDD are currently 
excluded from having a diagnosis of ADHD according to 
DSM-IV criteria, although they could benefit from treatment 
for their ADHD symptoms. They are also excluded from many 
research studies of ADHD despite the fact that they could rep-
resent one extreme of the distribution of neurodevelopmental 
disorders. The same is also true for children with ADHD and 
intellectual disability/mental retardation (IQ , 70).
The commonest comorbid disorders are CD and ODD. 
Their prevalence in children with ADHD ranges from 
20%–40% and they increase the risk of poor outcomes in 
children with ADHD. It has been considered that the group 
of children with ADHD and childhood-onset CD is distinct 
from the groups of children with ADHD or CD only. In 
this comorbid group of children, ADHD is more severe and 
shows greater persistence in adult life.21 Family history is also 
  stronger1 and the presence of CD indicates higher genetic 
loading in ADHD.22 Early onset CD also represents a risk 
factor for poor outcome for children with ADHD.23
To conclude, ADHD can co-exist with a wide range of 
psychiatric disorders and this could be due to shared inher-
ited factors. The presence of CD appears to be an index of 
heterogeneity.
Sex differences
There are higher rates of ADHD in males compared with 
females. The male to female ratio in population cohorts 
is approximately 4:1.18 However, sex difference ratios are 
larger in clinical samples (7–8:1) than population cohorts 
due to referral biases, since boys with ADHD tend to be 
more disruptive than girls, making them more likely to be 
referred.24 The phenotype of the disorder also differs between 
the two sexes. Boys tend to be more hyperactive, while 
girls are usually more inattentive.18 Research on the factors 
contributing to sex differences in ADHD has been limited. 
One possibility is that different genetic factors operate for 
males and females, although family studies show that ADHD 
in both sexes is familial and twin studies do not find major 
differences in the magnitude of genetic influences on ADHD 
in males and females.25
In summary, sex differences in the prevalence and clinical 
presentation of ADHD are well-established but more research 
is required to explain these.
The contribution of gene-environment 
interplay in ADHD
It is well-recognized that psychiatric disorders, like other 
complex diseases, are influenced by both genetic and environ-
mental factors.26 Gene-environment interplay encompasses 
both gene-environment correlation and gene-environment 
interaction.
Several environmental factors have been considered in 
relation to ADHD, including low birth weight,   prematurity, 
prenatal maternal smoking, alcohol consumption,   maternal 
stress, psychosocial adversity and poor maternal diet, and 
toxins during the prenatal or neonatal period.27 It is notable 
that the common characteristic of these environmental risks 
is that exposure is required during a critical period. For this 
reason it has been suggested that they might result in epi-
genetic (noninherited genomic) processes being   triggered 
during a developmental window.7
Gene-environment correlation
Gene-environment correlation applies when exposure 
to a certain environmental factor depends on the genetic 
make-up of the individual or their parents. This means 
that genes could increase the risk of developing ADHD Neuropsychiatric Disease and Treatment 2010:6 submit your manuscript | www.dovepress.com
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by influencing   exposure to certain environmental factors. 
In gene-  environment correlation the risk effects of genes 
and environment are not distinct and genes may indirectly 
increase risk to ADHD by influencing exposure to risk and 
protective factors. For example, maternal smoking and stress 
in pregnancy have both been linked to ADHD. However 
there is evidence to suggest that these environmental risks 
are influenced by maternally-provided inherited factors28 and 
index inherited liability to ADHD.
Gene-environment interaction
Gene-environment interaction is used to describe the 
  phenomenon whereby a genetic factor exerts its effect when 
the individual is exposed to environmental risk.29 Twin 
or adoption studies of ADHD on this topic have not been 
  published, although this could indicate a publication bias 
against negative results.29 Investigating gene-environment 
interaction in ADHD for specific gene variants is still at an 
early stage and there is a lack of robust replication studies. 
These results will be discussed later.
To conclude, most of the environmental factors that are 
considered to increase susceptibility to ADHD are prenatal 
risks. However, some studies highlight that risk factors 
  associated with a disorder are not necessarily causal.26
Molecular genetics of ADHD
Psychiatric disorders, including ADHD, are categorized as 
complex disorders; this means that, they are the result of 
multiple gene co-action, gene–gene and gene–  environment 
co-actions and interactions. The process of identifying 
complex disorder susceptibility genes has so far mainly 
been based on examining common variation in the DNA of 
different individuals without necessarily being pathogenic 
(for more information see Thapar and Stergiakouli30). This 
variation provides genetic markers/polymorphisms, such 
as single nucleotide polymorphisms (SNPs). Advances in 
technology have made mass genotyping of large numbers 
of SNPs for very big samples possible and more economi-
cal. The main three methods that have been used to identify 
common, susceptibility gene variants are:
•  whole genome linkage studies
•  candidate gene association studies
•  genome-wide association studies (GWAS).
Whole genome linkage studies
Whole genome linkage studies are based on families with 
multiple affected individuals, mainly affected sibling pairs, 
and aim to identify broad regions in the genome that could 
harbor susceptibility genes. The principle is that, if an allelic 
marker is linked to a susceptibility locus, affected relatives 
will share this allele more commonly than expected. Whole 
genome linkage studies of ADHD have been published and 
a meta-analysis of seven independent linkage scans yielded a 
significant association for 16q23 (PSR = 0.00034, POR = 0.04). 
Interestingly, the same region came to light from a GWAS 
of quantitative traits related to ADHD. This region harbors 
the CDH13 gene which has been implicated in substance 
use disorders.31
In summary, whole genome linkage studies have not been 
able to achieve replication or point unequivocally to regions 
harboring susceptibility genes for ADHD. This probably 
reflects the fact that there are no common susceptibility genes 
of large effect sizes for ADHD and whole genome linkage 
studies are not the most appropriate approach for identifying 
genes of smaller effect sizes.
Candidate gene association studies
Candidate gene association studies select genes that are 
hypothesized to be implicated in a disorder and then com-
pare the frequencies of marker alleles in affected individuals 
(cases) and healthy individuals (controls). Genes are selected 
on the basis of findings from whole genome linkage, animal, 
pharmacological or imaging studies. However, these studies 
are based on assumptions about the pathophysiology of the 
disorder and since this is largely unknown in psychiatric 
disorders, they have not been very successful.
Genes within the dopaminergic pathway have been 
hypothesized to be implicated in the pathophysiology of 
ADHD due to the therapeutic effects of stimulant   medication, 
which reduces ADHD symptoms by inhibiting the reuptake 
of dopamine.32 Animal studies also show that the dopamine 
transporter (DAT1) knockout mouse model (where the DAT1 
gene has been turned off to study the effects on the phenotype) 
exhibits hyperactivity and deficits in inhibitory behavior33 and 
imaging studies of patients with ADHD   provide evidence 
of changes in brain regions where   dopaminergic systems 
are more active.34 Genes on the dopaminergic pathway that 
have been investigated in relation to ADHD include dopamine 
D4 receptor gene (DRD4), dopamine D5 receptor gene 
(DRD5), DAT1 and catechol-O-methyltransferase (COMT). 
Other genes notably serotonergic genes and synaptosome-
associated proteins (SNAP-25) have also been studied.35 
According to a recent meta-analysis there is evidence that 
the serotonin transporter gene and the serotonin 1B   receptor 
gene might be associated with ADHD.36 However, since 
candidate gene association findings are not the focus of this Neuropsychiatric Disease and Treatment 2010:6 submit your manuscript | www.dovepress.com
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review, we will only discuss consistently replicated findings 
from meta-analyses or pooled analyses.
DRD4
The best studied DRD4 gene polymorphism is a variable 
number tandem repeat (VNTR) in exon III of the gene. 
The number of repeats ranges from 2–11 and the 7-repeat 
allele reduces the ability of the receptor to bind dopamine 
according to in vitro studies. A significant association of 
the 7-repeat allele and ADHD has been reported in four 
different meta-analyses and pooled studies.1,36–38 The most 
recent meta-analysis by Gizer et al36 reported a significant, 
modest association between ADHD and the 7-repeat allele 
(P , 0.00001, OR-1.27, 95% confidence interval [CI]: 
1.16–1.39), although the authors also showed evidence of 
substantial heterogeneity in effect sizes across different stud-
ies.36 Two studies have also suggested that the 7-repeat allele 
is associated with ADHD symptom persistence39,40 although 
findings are not entirely consistent.41
DRD5 gene
Another dopaminergic gene, the DRD5 has been investigated 
in relation to ADHD and the 148-bp allele of a   microsatellite 
at the 5′ end of the gene was found to be significantly 
  associated with ADHD in four meta-analytic studies.36,42–44 
The most recent meta-analysis reported a significant 
association (P = 0.000095, OR = 1.22, 95% CI: 1.10–1.36) 
with moderate heterogeneity in reported effect sizes.36 
Although these results are very promising, the associated 
polymorphism is not located in the protein coding region 
of the gene and has no known function; it could be that this 
polymorphism is co-inherited with another polymorphism 
that is functional or that it influences gene function in a yet 
unknown fashion.
Solute carrier family 6A, member 3  
(SLC6A3 or DAT1)
A VNTR polymorphism in the three-prime-untranslated 
region (3′ UTR) of the DAT1 gene has been extensively 
investigated and a significant association between the 
480-bp allele and ADHD (P = 0.002, OR = 1.1, 95% 
CI: 1.03–1.17) was found in an updated meta-analysis by 
Gizer et al.36 The same meta-analysis found   significant 
associations with other   polymorphisms in the DAT1 
gene and substantial heterogeneity across studies. 
Significant association of the 480-bp allele and ADHD 
has also been reported in five previous meta-analyses 
and pooled analyses.1,38,44–46 The International Multicenter 
ADHD Gene (IMAGE) project, a study of 776 ADHD cases 
that is the largest study to date, also reported a significant 
association but with a different polymorphism in the DAT1 
gene.47 Although the data indicates that DAT1 is a strong 
candidate gene for ADHD, most of the meta-analyses have 
found evidence of sample heterogeneity suggesting a very 
small effect size of this variant or the presence of multiple 
polymorphisms within the DAT1 gene increasing risk to 
ADHD. The DAT1 148-bp allele has been reported as 
increasing sensitivity to the risk effects of maternal   smoking 
during pregnancy.48 Another study also found evidence of 
gene-environment interaction but with a different DAT1 
allele.49 In contrast, there have been two negative reports 
of gene-environment interaction in relation to maternal 
smoking in pregnancy and DAT1.50,51 A further concern is 
that maternal smoking in pregnancy might not be a causal 
environmental risk but rather indexing inherited liability to 
ADHD.28   Prenatal exposure to alcohol was also investigated 
in ADHD and it was found that it increased ADHD 
symptoms when a specific haplotype of SNP alleles in DAT1 
was present.50 Two markers in the same gene, DAT1, have 
also been reported to interact with psychosocial adversity 
(defined by measures of family and parental adversity) and 
increase ADHD symptoms.52
COMT association with CD symptoms in patients 
with ADHD
The most studied polymorphism in COMT is a functional 
SNP resulting in a valine to methionine substitution 
(val158/108 met variant). However, two pooled analyses1,53 
and a meta-analysis36 have found no evidence of association 
between this variant and ADHD. Interestingly, the COMT 
val allele yielded an almost significant result for males in the 
Cheuk and Wong meta-analysis.53 Thus, it could potentially 
be involved in male susceptibility to ADHD.53
There is however consistent evidence that the COMT 
val/val genotype is associated with CD symptoms in those 
with ADHD.54 Since the first report, the same genotype was 
subsequently found to be associated with antisocial   behavior 
in those with ADHD (but not in those without ADHD) in two 
independent populations from United Kingdom and New 
Zealand birth cohorts.55 A pooled analysis of four studies also 
showed significant association with the val/val genotype.55 
The same genotype was also associated with increased 
aggressive CD symptoms in patients with ADHD.56 These 
results suggest that some gene variants operate by modify-
ing the ADHD phenotype rather than by increasing risk of 
disorder itself.Neuropsychiatric Disease and Treatment 2010:6 submit your manuscript | www.dovepress.com
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To summarize, the most robust evidence is for 
an   association between the DRD4 VNTR, the DRD5 
  microsatellite marker, the DAT1 480-bp VNTR and ADHD. 
It is still unclear whether the DRD4 VNTR is causal. The 
DRD5 148-bp microsatellite is 18.5 kb away from the gene 
but that does not mean it does not influence DRD5 in a yet 
unknown fashion. As for DAT1, there is significant evidence 
of   heterogeneity across studies, although it initially appeared 
as the strongest candidate gene. The evidence that the COMT 
val/val genotype has a modifying effect on antisocial behavior 
in ADHD is a consistent finding in the field of ADHD, since 
it has been replicated in multiple independent samples. At 
present there is no convincing evidence of gene-environment 
interaction in relation to ADHD.
GWAS
GWAS are currently regarded by many as the most promising 
method for systematically searching for complex disorder 
susceptibility genes. They involve testing several thousand 
or millions of SNPs across the genome without an a priori 
hypothesis, and it is believed that they will also be able to 
pick up genes of small effect. A major limitation is that they 
require extremely large sample sizes to overcome the problem 
of multiple testing and to avoid false-positive results that 
are simply the product of chance. Genome-wide association 
findings have been published for schizophrenia,57–59 bipolar 
disorder,60 autism61 and other psychiatric disorders. For a 
review of GWAS on ADHD see Franke et al.62
GWAS of ADHD have been undertaken but research is at 
a much earlier stage than for most other psychiatric disorders. 
The first such study used a sample of 959 family trios col-
lected as part of the IMAGE I study63 with 600,000 genotyped 
SNPs.63 Although, none of the associated SNPs reached 
genome-wide significance, these results do not exclude the 
existence of genes that increase risk for ADHD. In a list of the 
top-25 SNPs, there were some interesting candidate genes for 
ADHD, including cannabinoid receptor 1 (CNR1).31 This gene 
is located in a region that is possibly associated with ADHD 
according to a recent meta-analysis of linkage   studies64 and 
it has been also associated with alcohol and drug abuse63 
but such findings require replication in a different ADHD 
sample. Results from the same genome-wide scan were used 
to test for association with quantitative   phenotypes generated 
from the ADHD symptoms.65 The authors tested three 
quantitative phenotypes (number of   hyperactive-impulsive 
symptoms, number of inattentive symptoms and total num-
ber of symptoms) under three   different genetic models, 
which increased the multiple testing burden. There were 
two genome-wide significant results; one of them was an 
intronic SNP in Cadherin 13 (CDH13) associated with the 
total number of ADHD symptoms66 and the other one was 
an intronic SNP in glucose-fructose oxidoreductase-domain 
containing 1 (GFOD1) associated with the number of inat-
tentive symptoms. CDH13 has been previously reported to 
be associated with substance abuse63 and was on the list of 
the top-25 SNPs from the previous GWAS,65 although the 
two studies are not independent.
Based on a list of candidate genes for ADHD   compiled 
a priori, SNPs within Sodium/hydrogen exchanger 9 
(SLC9A9), as well as other genes previously associated 
with ADHD, were associated with the disorder, although 
they failed to reach genome-wide significance.67 Apart from 
being the top hit, SLC9A9 also contained the largest number 
of associations in terms of SNPs and phenotypes. However, 
it was also the largest gene in this study.
A pooled GWAS not associated with IMAGE 1 analyzed 
343 adult patients with persistent ADHD and 304 controls 
from Germany.67 Although again there were no genome-wide 
significant findings, a large proportion of the top-ranked 
SNPs were located in genes expressed in the brain and some 
of them, have also shown association with substance abuse 
disorders, which are found very frequently in adult ADHD 
patients.31
In terms of overlap of GWAS findings in ADHD, CDH13 
on chromosome 16q24.2–24.3 stands out. This gene is further 
supported by the fact that it falls into the only significant link-
age region from the meta-analysis by Zhou et al.66 Although 
CDH13 is not a classic candidate gene for ADHD, it codes for 
a cell-cell adhesion protein and is also a regulator of neural 
cell growth. Other interesting findings in the top-ranked 
results of these GWAS relate to Tolloid-like (TLL) genes.68 
They code for metalloproteases that cleave collagen and they 
are expressed in the brain. These findings highlight the fact 
that GWAS can point to novel risk pathways that would not 
be otherwise explored. However, caution is required given 
that no findings have achieved genome-wide significance 
levels or yet been replicated.
The IMAGE dataset was also used to perform a GWAS 
on ADHD with comorbid CD,54 which as discussed earlier is 
considered to index heterogeneity.68 There were no reported 
genome-wide significant associations, although 54 markers 
were nominally associated. However, the authors point out 
that their analysis was exploratory and any associations 
would require replication.69
In summary the first findings from GWAS on ADHD have 
provided some interesting genes to explore while failing to Neuropsychiatric Disease and Treatment 2010:6
Table 1 Key findings from molecular genetic studies of ADHD
Gene Type of studies Evidence Function
DRD4 7-repeat allele Association studies and  
meta-analysis47
Consistent G protein-coupled receptor that  
binds dopamine
DRD5 148-bp  
microsatellite repeat
Association studies and  
meta-analysis47
Consistent G protein-coupled receptor that  
binds dopamine
DAT1 480-bp VNTR Association studies and  
meta-analysis47
Mixed evidence Membrane-spanning protein that  
removes dopamine from the  
synaptic cleft
COMT Val158Met Association studies and  
meta-analysis47
Not associated with ADHD but  
associated with CD in ADHD
Enzyme catalyzing the degradation   
of dopamine, adrenaline and  
noradrenaline
CDH13 Genome-wide  
association studies65,67
Overlap from GWAS studies but  
needs replication
Cell-cell adhesion protein and  
regulator of neural cell growth
GFOD1 Genome-wide  
association studies65,67
Overlap from GWAS studies but  
needs replication
Predicted to be involved in  
electron transport and metabolic  
processes
TLL Genome-wide  
association studies63,65,67
Overlap from GWAS studies but  
needs replication
Metalloproteases that cleave  
collagen, expressed in brain
Abbreviations: GWAS, genome-wide association study; DRD4, dopamine D4 receptor gene; DRD5, dopamine D5 receptor gene; DAT1, dopamine transporter gene; 
COMT, catechol-o-methyltransferase; CDH13, cadherin 13; GFOD1, glucose-fructose oxidoreductase-domain containing 1; TLL, tolloid-like genes.
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provide support for previous candidate genes and achieve 
any genome-wide significant results (Table 1). As GWAS 
of other complex disorders have shown,70 the effect sizes of 
common variants are very small and this in practice means 
that success will only be possible if sample sizes are greatly 
increased. Collaborative efforts can help achieve the number 
of patients and healthy controls needed to have sufficient 
power to detect such small effects.
Other potential reasons for the limited success of ADHD 
GWAS are sample heterogeneity, and the fact inherited fac-
tors other than common variants could increase risk for com-
plex disorders. Although rare variants are found in a small 
proportion of the population (usually less than 5%), their 
effect sizes can be far greater than those for common variants, 
since they are more likely to have important implications for 
gene function than common variants (Table 1).
Copy number variants (CNVs)
One category of rare variants includes CNVs, which are DNA 
segments, of at least 1 kb in size, that vary in number when 
genomes of different individuals are compared. They can be 
copy number gains (called insertions or duplications), when 
there is a relative gain of a DNA segment compared to the 
control genome, or they can be copy number losses (called 
deletions), when there is a relative loss of a DNA segment. 
The presence of a CNV in an individual does not necessarily 
mean that there is a phenotypic effect, since CNVs are part 
of the normal variation of the human genome.71 However, 
it has emerged that large, rare CNVs can increase risk of 
disorder, especially those of a neurodevelopmental nature 
such as autism72 and mental retardation; thus the advances 
in technology that have made CNV detection more cost and 
time effective are very welcome.
Studies of CNVs in ADHD have just started to emerge. 
The first published study of CNVs in ADHD did not find 
increased numbers of deletions or duplications in ADHD 
compared to controls.72 However, authors report that the 
gene set associated with inherited rare CNVs in cases was 
significantly enriched for genes previously studied in rela-
tion to autism, schizophrenia, and Tourette’s syndrome.36 
Another study of CNVs in ADHD reported rare deletions 
and duplications in a sample of 99 children and adolescents 
with severe ADHD.73 One of the duplications encompassed 
the gene neuropeptide Y (NPY), which has been implicated 
in behavioral traits and other psychiatric disorders74 as well as 
being involved in energy balance. Although CNV studies in 
ADHD are still in their infancy, they could point to new risk 
pathways for ADHD and highlight overlaps across different 
neurodevelopmental disorders.
Summary and future directions
ADHD is a complex disorder with high heritability. CD 
may index aetiological as well as clinical heterogeneity. 
There also appear to be shared inherited links with autism 
symptoms and CD. Candidate gene association studies have 
been more successful for ADHD than for other psychiatric 
disorders, but associated gene variants still explain only a 
small percentage of the inherited component of ADHD.61,75 
GWAS on ADHD have only just started to emerge, so it 
is still too early to completely trust their findings unless Neuropsychiatric Disease and Treatment 2010:6 submit your manuscript | www.dovepress.com
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  replication in independent samples is achieved. In the future, 
much larger samples will be required through international 
collaborative efforts.
Although large samples will be needed, careful, detailed 
clinical and phenotype assessments are still important. ADHD 
is heterogeneous and phenotype refinement could potentially 
lead to more success in identifying genetic risk factors. Also 
such assessments are important if gene-phenotype links are to 
be examined. Epidemiological, cognitive neuroscience and 
imaging studies can also be helpful in examining the risk 
effects of putative ADHD genes in normal individuals. For 
example, examining the effects of such genetic variants 
on brain structure and function as well as other potential 
  “intermediate phenotypes” could help identify risk mecha-
nisms for ADHD as well as a better understanding of brain 
function in normal individuals.
The next few years are likely to be very exciting for the 
field of ADHD genetics. The first findings from GWAS are 
pointing to neuronal cell migration and plasticity but also 
more basic processes, like cell division and extracellular 
matrix regulation, which have not been considered before.76 
New technologies, such as next generation sequencing, are 
likely to enhance our capacity to examine the contribution 
of common and rare variants as well as CNVs.77 This tech-
nology has already been applied to sequence ∼1000 human 
genomes as part of the 1000 genomes project. For the first 
time an unprecedented amount of genetic variation has 
become available for testing for association with complex 
disorders.
To conclude, a number of consistent genetic findings 
have emerged in relation to ADHD. Advances in technology 
and statistical analysis methods, improvements in phenotype 
  definition and collaborative efforts to enhance sample sizes 
will be critical to identify and replicate more susceptibility 
genes. If and when some of these findings are replicated, 
the challenge will be to test for causal mechanisms at a 
  biological and clinical level. Such research provides the 
first step towards understanding the pathogenesis of ADHD 
and reaching the final goal of improving diagnosis and 
treatment.
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